SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity | Zendy

Naveen Gupta | Zendy; Roland Liu | Zendy; Stephanie Shin | Zendy; Ranjeet Sinha | Zendy; Joseph Pogliano | Zendy; Kit Pogliano | Zendy; John H. Griffin | Zendy; Victor Nizet | Zendy; Ross Corriden | Zendy

Open Access

SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity

Author(s) -

Naveen Gupta,

Roland Liu,

Stephanie Shin,

Ranjeet Sinha,

Joseph Pogliano,

Kit Pogliano,

John H. Griffin,

Victor Nizet,

Ross Corriden

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky033

Subject(s) - neutrophil extracellular traps , pneumonia , cathelicidin , sepsis , immunology , bacterial pneumonia , medicine , microbiology and biotechnology , inflammation , antibiotics , biology , antimicrobial peptides , antimicrobial

The role of protease-activated receptor 1 (PAR1) in the pathogenesis of pneumonia and sepsis is ambiguous given the existing literature. As PAR1 is classically activated by the coagulation-based protease thrombin and leads to vascular leakage, our hypothesis was that PAR1 blockade with SCH79797 would be therapeutically beneficial in an experimental model of murine Gram-negative pneumonia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research